A Phase 3 interventional study of atorvastatin and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 14th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 50 in phase 3, and was the 15th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 579 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 24th largest by enrollment of the 81 interventional ones that give a count, is one of 7 that started in 2006, is one of 58 in phase 3, and was the 26th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To Evaluate and Compare the Efficacy and Safety of Ezetimibe Plus Atorvastatin Versus Atorvastatin in Hypercholesterolemic Patients at High Risk for Coronary Heart Disease Not Adequately Controlled on Atorvastatin 40 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Atorvastatin 80 mg
Drug: atorvastatin
Atorvastatin 40 mg + ezetimibe 10 mg
Drug: atorvastatin · Drug: ezetimibe
Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
Atorvastatin 40 mg by mouth, once a day for 6 weeks
Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C
Percent Change in LDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 weeks
Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)
Percent Change in HDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 weeks
Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
Percent Change in Non-HDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Total-Cholesterol
Percent Change in Total-C = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Triglycerides (TG)
Percent Change in TG = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)
Percent Change in Apo B = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)
Percent Change in Apo A-I = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio
Percent Change in TC:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio
Percent Change in LDL-C:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio
Percent Change in Apo B:Apo A-I Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio
Percent Change in non-HDL-C:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
Time frame: Baseline and 6 Weeks
Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)
Percent Change in CRP = \[(week 6 value - baseline value)/baseline value\]\*100%
Time frame: Baseline and 6 Weeks
Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
Time frame: 6 Weeks
Phase III First Patient In: 4/6/2006; Last Patient Last Visit 2/26/2008 96 centers worldwide (US, Canada) Eligible patients include those on a stable dose of atorvastatin 40 mg; or patients with adjusted LDLC pre-screen ranges who were treated with other lipid modifying therapy, or were statin and/or ezetimibe naïve.
| Milestone | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Started | 288 | 291 |
| Completed | 279 | 278 |
| Not completed | 9 | 13 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Could not take time off work | 0 | 1 |
Percent Change in LDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C | -27.4 (-29.6 to -25.1) | -11.0 (-13.2 to -8.8) |
Percent Change in HDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C) | -0.5 (-1.6 to 0.7) | -1.0 (-2.1 to 0.2) |
Percent Change in Non-HDL-C = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) | -23.3 (-25.3 to -21.4) | -9.0 (-11.0 to -7.1) |
Percent Change in Total-C = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Total-Cholesterol | -16.9 (-18.3 to -15.4) | -6.9 (-8.4 to -5.5) |
Percent Change in TG = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Triglycerides (TG) | -12.3 (-16.3 to -8.2) | -5.9 (-10.2 to -0.7) |
Percent Change in Apo B = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B) | -17.8 (-19.6 to -16.0) | -7.7 (-9.5 to -5.8) |
Percent Change in Apo A-I = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I) | -0.3 (-1.5 to 0.9) | -1.2 (-2.3 to -0.0) |
Percent Change in TC:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio | -16.0 (-176.6 to -14.4) | -5.6 (-7.2 to -4.1) |
Percent Change in LDL-C:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
| Percent change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio | -26.4 (-28.8 to -24.0) | -9.9 (-12.3 to -7.5) |
Percent Change in Apo B:Apo A-I Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio | -16.9 (-18.9 to -14.9) | -5.9 (-7.9 to -3.9) |
Percent Change in non-HDL-C:HDL-C Ratio = \[(week 6 ratio - baseline ratio)/baseline ratio\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio | -22.2 (-24.5 to -19.9) | -7.6 (-9.9 to -5.4) |
Percent Change in CRP = \[(week 6 value - baseline value)/baseline value\]\*100%
| Percent Change | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Percent Change From Baseline to Week 6 in C Reactive Protein (CRP) | -18.3 (-25.0 to -11.1) | -11.5 (-18.7 to -3.6) |
| Participants | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| <70 mg/dL | 204 | 88 |
| >=70 mg/dL | 73 | 191 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin + Ezetemibe | — | — | — |
| Atorvastatin | — | — | — |
| Event | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Myocardial infarctionCardiac disorders | 3/286 | 1/289 |
| Cardiac failure congestiveCardiac disorders | 1/286 | 0/289 |
| Chest painGeneral disorders | 1/286 | 0/289 |
| Non-cardiac chest painGeneral disorders | 1/286 | 0/289 |
| PneumoniaInfections and infestations | 1/286 | 0/289 |
| PresyncopeNervous system disorders | 1/286 | 0/289 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/286 | 0/289 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 1/286 | 0/289 |
| Hypertensive crisisVascular disorders | 1/286 | 0/289 |
| Labile hypertensionVascular disorders | 1/286 | 0/289 |
| Event | Atorvastatin + Ezetemibe | Atorvastatin |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/286 | 7/289 |
| DiarrhoeaGastrointestinal disorders | 0/286 | 6/289 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/286 | 5/289 |
| BronchitisInfections and infestations | 4/286 | 1/289 |
| NasopharyngitisInfections and infestations | 4/286 | 1/289 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/286 | 3/289 |
| HeadacheNervous system disorders | 4/286 | 2/289 |
| FatigueGeneral disorders | 0/286 | 4/289 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/286 | 4/289 |
| Myocardial infarctionCardiac disorders | 3/286 | 1/289 |
| Age, Continuous(years) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 60.6 (31 to 80) | 62 (34 to 79) | 61.3 (31 to 80) |
| Sex: Female, Male(Participants) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Female | 115 | 113 | 228 |
| Male | 173 | 178 | 351 |
| Race/Ethnicity, Customized(Participants) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| White | 237 | 232 | 469 |
| Asian | 4 | 8 | 12 |
| Black | 32 | 29 | 61 |
| Multi-Racial | 15 | 22 | 37 |
| Apolipoprotein A-I(mg/dL) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 154.0 ± 25.5 | 154.6 ± 25.0 | 154.3 ± 25.3 |
| Apolipoprotein B(mg/dL) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 101.3 ± 19.0 | 102.0 ± 18.8 | 101.7 ± 18.9 |
| Apolipoprotein B:Apolipoprotein A-I ratio(Ratio) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 0.7 ± 0.2 | 0.7 ± 0.2 | 0.7 ± 0.2 |
| C Reactive Protein(mg/dL) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 1.8 ± 2.7 | 1.5 ± 3.0 | 1.6 ± 2.8 |
| High-Density Lipoprotein(mg/dL) | Atorvastatin + Ezetemibe | Atorvastatin | Total |
|---|---|---|---|
| Mean | 47.4 ± 10.5 | 47.2 ± 10.6 | 47.3 ± 10.5 |
7 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
The record gives a start of Feb 2006, a primary completion of Feb 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe